Patents by Inventor John E. Park

John E. Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A-beta binding polypeptides
    Patent number: 9211330
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmerman, Gerald Beste, Toon Laeremans, Pascal Gerard Merchiers, Jo Vercammen
  • A-BETA BINDING POLYPEPTIDES
    Publication number: 20140030275
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • Nucleic acid molecules encoding A-beta binding polypeptides
    Patent number: 8614308
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 24, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
  • A-BETA BINDING POLYPEPTIDES
    Publication number: 20130017209
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • A-beta binding polypeptides
    Patent number: 8337845
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
  • A-BETA BINDING POLYPEPTIDES
    Publication number: 20120058118
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Application
    Filed: March 2, 2011
    Publication date: March 8, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
  • Isolated proteins containing portions of FAP? and other proteins
    Patent number: 6846910
    Abstract: The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or “FAP?” and its uses.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: January 25, 2005
    Assignees: Ludwig Institute for Cancer Research, Boehringer Ingelheim International GmbH
    Inventors: Rainer Zimmermann, John E. Park, Wolfgang Rettig, Lloyd J. Old
  • FAP-activated anti-tumour compounds
    Patent number: 6613879
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: September 2, 2003
    Assignees: Boehringer Ingelheim Pharma KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Raymond A. Firestone, Wolfgang J. Rettig, Martin Lenter, Stefan Peters, Pilar Garin-Chesa, Juergen Mack, Dietmar Leipert, John E. Park, Leila A. Telan
  • ISOLATED PROTEINS CONTAINING PORTIONS OF FAPALPHA AND OTHER PROTEINS
    Publication number: 20020034789
    Abstract: The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or “FAP&agr;” and its uses.
    Type: Application
    Filed: March 10, 1999
    Publication date: March 21, 2002
    Inventors: RAINER ZIMMERMANN, JOHN E. PARK, WOLFGANG RETTIG, LLOYD J. OLD
  • Isolated dimeric fibroblast activation protein .alpha., and uses thereof
    Patent number: 5965373
    Abstract: The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or "FAP.alpha." and its uses.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: October 12, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Rainer Zimmermann, John E. Park, Wolfgang Rettig, Lloyd J. Old
  • Isolated dimeric fibroblast activation protein alpha, and uses thereof
    Patent number: 5767242
    Abstract: The invention involves dimeric forms of the protein known as fibroblast activation protein alpha, or "FAP.alpha." and its uses.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: June 16, 1998
    Assignees: Boehringer Ingelheim Int'l GmbH, Ludwig Institute For Cancer Research
    Inventors: Rainer Zimmermann, John E. Park, Wolfgang Rettig, Lloyd J. Old